- Home
- HYMC vs ICUI Comparison
HYMC vs ICUI Comparison
Compare HYMC & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYMC | ICUI |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | HYMC | ICUI |
|---|---|---|
| Price | $21.45 | $142.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $169.00 |
| AVG Volume (30 Days) | ★ 2.1M | 264.7K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.46 |
| P/E Ratio | ★ N/A | $112.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $107.02 |
| 52 Week High | $58.73 | $160.29 |
Technical Indicators
Market Signals| Indicator | HYMC | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 59.55 |
| Support Level | $6.49 | $139.88 |
| Resistance Level | $29.65 | $143.78 |
| Average True Range (ATR) | 2.11 | 4.47 |
| MACD | -0.21 | -0.43 |
| Stochastic Oscillator | 4.77 | 77.76 |
Price Performance
Historical ComparisonAbout HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a United States-based gold and silver exploration-stage issuer. The company owns and is focused on developing its property, the Hycroft Mine, located northwest of Winnemucca, Nevada.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.